Aurora has demonstrated improving operational metrics despite bottom-line volatility.
: While adjusted EBITDA reached $18.5 million , Aurora still reported a net loss of $51.6 million in Q3 2026, driven by costs rather than top-line movement alone. buy acb stock
Professional outlooks on ACB are mixed, balancing its medical leadership against broader sector risks. As of April 28, 2026, Aurora Cannabis (ACB)
As of April 28, 2026, Aurora Cannabis (ACB) is trading at , reflecting a 19.12% decline year-to-date . The company is currently executing a strategic shift to prioritize high-margin global medical cannabis markets over lower-margin consumer segments. Aurora Cannabis Inc (ACB) -19.12% since Jan 2, 2026 Closed: 4:00 PM • Disclaimer After hours: 7:30 PM Apr 27, 2026 Mkt cap$271.06M CAD 52-wk high6.67 P/E ratio- 52-wk low3.07 Div yield- Financial Performance & Health Market Sentiment & Ratings : The company maintains
: Global medical cannabis now accounts for 81% of total revenue and 95% of adjusted gross profit , with medical margins holding steady at 69% . Market Sentiment & Ratings
: The company maintains a "cannabis debt-free" balance sheet with $154.4 million in cash as of December 31, 2025.